U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CEL-SCI (NYSE: CVM) announced FDA agreement on using PD-L1 biomarker for patient selection in its upcoming Multikine Registration Study for head and neck cancer, starting Q1 2025. The study will focus on patients with low PD-L1 tumor expression, following promising results from a previous Phase 3 study where patients showed 73% vs. 45% five-year survival rate compared to control group. The new study will enroll approximately 212 patients with newly diagnosed locally advanced primary head and neck cancer without lymph node involvement. Multikine shows better effectiveness in patients with low PD-L1 expression, which represents about 70% of head and neck cancer cases.
CEL-SCI (NYSE: CVM) ha annunciato l'accordo della FDA per l'uso del biomarker PD-L1 nella selezione dei pazienti per il suo prossimo studio di registrazione Multikine per il cancro testa-collo, che avr脿 inizio nel primo trimestre del 2025. Lo studio si concentrer脿 su pazienti con bassa espressione tumorale di PD-L1, dopo i risultati promettenti di un precedente studio di fase 3 in cui i pazienti hanno mostrato un tasso di sopravvivenza a cinque anni del 73% contro il 45% rispetto al gruppo di controllo. Il nuovo studio recluter脿 circa 212 pazienti con cancro testa-collo primario localmente avanzato di recente diagnosi, senza coinvolgimento dei linfonodi. Multikine mostra una maggiore efficacia nei pazienti con bassa espressione di PD-L1, che rappresentano circa il 70% dei casi di cancro testa-collo.
CEL-SCI (NYSE: CVM) anunci贸 el acuerdo de la FDA para usar el biomarcador PD-L1 en la selecci贸n de pacientes para su pr贸ximo estudio de registro de Multikine para el c谩ncer de cabeza y cuello, que comenzar谩 en el primer trimestre de 2025. El estudio se centrar谩 en pacientes con baja expresi贸n tumoral de PD-L1, tras los resultados prometedores de un estudio de fase 3 anterior donde los pacientes mostraron un tasa de sobrevivencia del 73% frente al 45% en comparaci贸n con el grupo de control. El nuevo estudio inscribir谩 aproximadamente a 212 pacientes con c谩ncer de cabeza y cuello primario localmente avanzado reci茅n diagnosticado, sin involucramiento de ganglios linf谩ticos. Multikine muestra una mejor eficacia en pacientes con baja expresi贸n de PD-L1, que representan aproximadamente el 70% de los casos de c谩ncer de cabeza y cuello.
CEL-SCI (NYSE: CVM)電� 雼り皜鞓る姅 霊愱步攵� 鞎旍棎 雽�頃� Multikine 霌彪 鞐瓣惮鞐愳劀 頇橃瀽 靹犾爼鞚� 鞙勴暣 PD-L1 氚旍澊鞓る旎�毳� 靷毄頃� 靾� 鞛堧嫟電� FDA鞚� 頃╈潣毳� 氚滍憸頄堨姷雼堧嫟. 鞐瓣惮電� 2025雲� 1攵勱赴攵�韯� 鞁滌瀾霅╇媹雼�. 鞚挫爠 3靸� 鞐瓣惮鞚� 鞙犽頃� 瓴瓣臣鞐� 霐半澕 PD-L1 膦呾枒 氚滍槃鞚� 雮潃 頇橃瀽鞐� 齑堨爯鞚� 毵烄稖 瓴冹瀰雼堧嫟. 攴� 鞐瓣惮鞐愳劀 頇橃瀽霌れ潃 雽�臁瓣蛋瓿� 牍勱祼頃橃棳 5雲� 靸濎〈鞙澊 73%雽� 45%毳� 雮橅儉雰堨姷雼堧嫟. 靸堧鞖� 鞐瓣惮電� 毽柬攧鞝� 旃矓 鞐嗢澊 靸堧…瓴� 歆勲嫧霅� 甑唽 歆勴枆靹� 霊愱步攵� 鞎� 頇橃瀽 鞎� 212氇呾潉 霌彪頃� 鞓堨爼鞛呺媹雼�. Multikine鞚� PD-L1 氚滍槃鞚� 雮潃 頇橃瀽鞐愳劀 雿� 雮橃潃 須臣毳� 氤挫澊氅�, 鞚措姅 霊愱步攵� 鞎� 靷鞚� 鞎� 70%毳� 彀頃╇媹雼�.
CEL-SCI (NYSE: CVM) a annonc茅 un accord avec la FDA pour utiliser le biomarqueur PD-L1 dans la s茅lection des patients lors de son prochain 茅tude d'enregistrement Multikine pour le cancer de la t锚te et du cou, qui d茅butera au premier trimestre 2025. L'茅tude se concentrera sur des patients avec une faible expression tumorale de PD-L1, suite 脿 des r茅sultats prometteurs d'une 茅tude de phase 3 pr茅c茅dente o霉 les patients ont montr茅 un taux de survie 脿 cinq ans de 73 % contre 45 % par rapport au groupe t茅moin. La nouvelle 茅tude inscrira environ 212 patients nouvellement diagnostiqu茅s avec un cancer primitif avanc茅 de la t锚te et du cou sans atteinte des ganglions lymphatiques. Multikine montre une meilleure efficacit茅 chez les patients avec une faible expression de PD-L1, repr茅sentant environ 70 % des cas de cancer de la t锚te et du cou.
CEL-SCI (NYSE: CVM) gab bekannt, dass die FDA dem Einsatz des PD-L1 Biomarkers zur Patienten Auswahl in ihrer bevorstehenden Multikine Registrierungsstudie f眉r Kopf- und Halskrebs zugestimmt hat, die im ersten Quartal 2025 beginnen wird. Die Studie wird sich auf Patienten mit geringer PD-L1 Tumorexpression konzentrieren, nach vielversprechenden Ergebnissen aus einer fr眉heren Phase-3-Studie, in der Patienten eine 5-Jahres-脺berlebensrate von 73% gegen眉ber 45% im Vergleich zur Kontrollgruppe zeigten. Die neue Studie wird voraussichtlich rund 212 Patienten mit neu diagnostiziertem lokal fortgeschrittenem prim盲rem Kopf- und Halskrebs ohne Lymphknoteneinbeziehung rekrutieren. Multikine zeigt eine bessere Wirksamkeit bei Patienten mit niedriger PD-L1-Expression, die etwa 70% der F盲lle von Kopf- und Halskrebs darstellen.
- Previous Phase 3 study showed significant survival improvement (73% vs 45%) in target population
- FDA agreement on patient selection method strengthens study design
- Large potential market as 70% of head and neck cancer patients have low PD-L1 expression
- Unique positioning in $48 billion global checkpoint inhibitor market
- New Registration Study won't start until Q1 2025
- patient enrollment of 212 participants in upcoming study
Insights
The FDA's agreement on using PD-L1 as a biomarker for patient selection represents a significant milestone for CEL-SCI's Multikine development. The data showing
The inverse relationship between PD-L1 levels and Multikine efficacy provides a clear differentiation from existing checkpoint inhibitors like Keytruda and Opdivo. This positions Multikine uniquely in the
This development strengthens CEL-SCI's market positioning in the head and neck cancer space. With Keytruda projected at
The FDA's agreement on the biomarker strategy adds regulatory clarity and reduces development risk. For a company with a
- Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study
-
Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of
73% vs.45% in the control group in the prior randomized controlled Phase 3 study
PD-L1 is a widely used biomarker for cancer patient selection for checkpoint inhibitors, a class of cancer drugs representing a
鈥淭o our knowledge, Multikine is the only neoadjuvant immunotherapy that has shown overall survival benefit in the low and negative PD-L1 head and neck cancer population. This underscores the critical importance of having reached an agreement with the FDA on the method for identifying and selecting patients with low PD-L1 tumor expression for our upcoming confirmatory Registration study,鈥� stated CEL-SCI CEO Geert Kersten.
鈥淧atient selection based on low PD-L1 as a biomarker can boost the success of our upcoming confirmatory trial, further enhancing our confidence based on the retrospective data from our Phase 3 study. We appreciate the ongoing dialog, exchange of ideas and information with the FDA in support of CEL-SCI鈥檚 groundbreaking work as we aim to treat an unmet need in cancer patients with low PD-L1 expression.鈥�
About CEL-SCI Corporation
CEL-SCI believes that boosting a patient鈥檚 immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.
Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the very strong data from the completed randomized controlled Phase 3 study, the FDA concurred with CEL-SCI鈥檚 target patient selection criteria and gave the go-ahead to conduct a small, focused, confirmatory Registration Study which will enroll 212 patients. CEL-SCI will enroll newly diagnosed locally advanced primary treatment na茂ve resectable head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing about 100,000 patients annually.
The Company has operations in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2023. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
View source version on businesswire.com:
Gavin de Windt
CEL-SCI Corporation
(703) 506-9460
Source: CEL-SCI Corporation
FAQ
When will CEL-SCI (CVM) start its new Multikine Registration Study?
What was the survival rate difference in CVM's Phase 3 Multikine study?
How many patients will CVM enroll in the new Multikine Registration Study?
What percentage of head and neck cancer patients have low PD-L1 expression suitable for CVM's Multikine?
